Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 37, 2016, Pages 10225-10227

  Lia, Jun Xu ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BU 08028; BUPRENORPHINE; OPIATE; OPIATE AGONIST; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANALGESIA; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FIRST PASS EFFECT; HUMAN; MEDICAL PRACTICE; NONHUMAN; OPIATE ADDICTION; PAIN; PLACE PREFERENCE; PRESCRIPTION; PRIORITY JOURNAL; THERAPY EFFECT; ANALOGS AND DERIVATIVES; RESEARCH;

ANALGESICS, OPIOID; BUPRENORPHINE; HUMANS; NARCOTIC ANTAGONISTS; RESEARCH;

EID: 84987607025     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1612752113     Document Type: Article

References (16)

1. Institute of Medicine (2011) Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research (National Academies, Washington, DC).
2. Ding H, et al. (2016) A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci USA 113:E5511-E5518.
3. Brownstein MJ (1993) A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA 90(12):5391-5393.
4. Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT (2016) Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 68(2):419-457.
5. Evans CJ, Keith DE, Jr, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a delta opioid receptor by functional expression. Science 258(5090):1952-1955.
6. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG (1992) The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 89(24):12048-12052.
7. Chen Y, Mestek A, Liu J, Hurley JA, Yu L (1993) Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44(1):8-12.
8. Viscusi ER, et al. (2016) A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain 157(1):264-272.
9. Orman JS, Keating GM (2009) Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs 69(5):577-607.
10. Raffa RB, et al. (2014) The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther 39(6):577-583.
11. Ko MC, et al. (2009) Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 34(9):2088-2096.
12. Kiguchi N, Ding H, Ko MC (2016) Central N/OFQ-NOP receptor system in pain modulation. Adv Pharmacol 75:217-243.
13. Neilan CL, et al. (2004) Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Eur J Pharmacol 499(1-2):107-116.
14. Khroyan TV, et al. (2011) The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): Characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward. J Pharmacol Exp Ther 336(3):952-961.
15. Phillips KA, et al. (2014) Why primate models matter. Am J Primatol 76(9):801-827.
16. Ator NA, Griffiths RR (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70(3, Suppl):S55-S72.